Pharmacology

Dolan, M Eileen

Abstract

The Pharmacology Core Facility conducts clinical pharmacology, biochemical correlates, andpharmacogenetic studies with the aim of improving the quality of life and outcome for cancer patients.The Facility is essential for the development, validation, and implementation of analytical methods toassess the effect of pharmacokinetics or pharmacodynamics, and for measuring biochemical correlatesnecessary to optimize drug administration schedules. Some novel anticancer therapies requiredetermination of the optimal dose based on a biochemical endpoint and the Pharmacology Core isequipped to define the bio-modulatory dose. The Facility offers DMA and RNA isolation forpharmacogenetic studies. The Scientific Director of the Facility is M. Eileen Dolan, PhD, and theTechnical Directors are Jacqueline Ramirez, MS (Analytical Component) and Shannon Delaney(Biochemical Component). Dr. Dolan has extensive experience in biochemical enzyme assays, drugmetabolism, and pharmacokinetic/pharmacodynamic studies of anticancer agents. Ms. Ramirez andDelaney are responsible for quality control, analytical method development, maintenance of analyticalequipment, and preparation of reports. The Facility renders analytical and biochemical services toinvestigators within the University (both members and non-members of the UCCRC), as well asinvestigators at other Cancer Centers. In addition, Dr. Dolan provides consultative services on studyand assay design.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Center Core Grants (P30)
• Project #: 2P30CA014599-33
• Application #: 7714295
• Study Section: Special Emphasis Panel (ZCA1-RTRB-N (J1))
• Project Start: 2008-07-22
• Project End: 2013-03-31
• Budget Start: 2008-07-22
• Budget End: 2009-03-31
• Support Year: 33
• Fiscal Year: 2008
• Total Cost: $82,879

Institution

• Name: University of Chicago
• DUNS #: 005421136
• City: Chicago
• State: IL
• Country: United States
• Zip Code: 60637

Publications

Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437

Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70

Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:

Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :

Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977

Ni, Kaiyuan; Lan, Guangxu; Chan, Christina et al. (2018) Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 9:2351

Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584

Webber, Jemma L; Zhang, Jie; Massey, Alex et al. (2018) Collaborative repressive action of the antagonistic ETS transcription factors Pointed and Yan fine-tunes gene expression to confer robustness in Drosophila. Development 145:

Wei, Jiangbo; Liu, Fange; Lu, Zhike et al. (2018) Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell 71:973-985.e5

Boisclair Lachance, Jean-François; Webber, Jemma L; Hong, Lu et al. (2018) Cooperative recruitment of Yan via a high-affinity ETS supersite organizes repression to confer specificity and robustness to cardiac cell fate specification. Genes Dev 32:389-401